- Home
- PHGE
as 07-26-2024 4:00pm EST
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
| Founded: | 2015 | Country: | Israel |
| Employees: | N/A | City: | NESS ZIONA |
| Market Cap: | 24.2M | IPO Year: | N/A |
| Target Price: | $2.25 | AVG Volume (30 days): | 206.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.19 - $0.85 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BiomX Inc. COmmon Stock News
PHGE Breaking Stock News: Dive into PHGE Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
GlobeNewswire
2 months ago
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
GlobeNewswire
2 months ago
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
GlobeNewswire
2 months ago
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
GlobeNewswire
2 months ago
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
GlobeNewswire
3 months ago
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
GlobeNewswire
3 months ago
BiomX Announces the Appointment of Susan Blum to its Board of Directors
Zacks
4 months ago
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
Compare PHGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHGE BiomX Inc. COmmon Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.